Evidence map›Paper›PMID 40527304›Full record

Trial reportThe American journal of tropical medicine and hygiene2025

Malaria Parasitemia after Mass Distribution of Azithromycin to Prevent Child Mortality in Burkina Faso: Results from a Cluster Randomized Trial.

Boubacar Coulibaly, Ali Sié, Mamadou Ouattara, Mamadou Bountogo, Guillaume Compaoré, Adama Compaoré, Moustapha Nikiema, Nestor Dembélé Sibiri, Jérôme Nankoné Tiansi, Elodie Lebas and 6 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Boubacar CoulibalyCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Ali SiéCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou OuattaraCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou BountogoCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Guillaume CompaoréCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Adama CompaoréCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Moustapha NikiemaCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Nestor Dembélé SibiriCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Jérôme Nankoné TiansiCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Elodie LebasFrancis I Proctor Foundation, University of California, San Francisco, California.
Ian FettermanFrancis I Proctor Foundation, University of California, San Francisco, California.
Huiyu HuFrancis I Proctor Foundation, University of California, San Francisco, California.
Thuy DoanFrancis I Proctor Foundation, University of California, San Francisco, California.
Benjamin F ArnoldFrancis I Proctor Foundation, University of California, San Francisco, California.
Thomas M LietmanFrancis I Proctor Foundation, University of California, San Francisco, California.
Catherine E OldenburgFrancis I Proctor Foundation, University of California, San Francisco, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The twice-yearly mass distribution of azithromycin to children aged 1-59 months reduces all-cause child mortality. It has been suggested in some studies that mass azithromycin distributions may reduce malaria mortality and parasitemia; however, these studies have been conducted in the absence of seasonal malaria chemoprevention (SMC). Here, we evaluate malaria parasitemia in a cluster randomized trial of azithromycin versus a placebo in Burkina Faso, where SMC was being administered. Thin and thick smears were taken from a random sample of 15 children per cluster in 40 clusters that had been receiving twice-yearly azithromycin or a placebo for 36 months (six distributions). We found no evidence of a difference in malaria parasitemia between children in the azithromycin and placebo clusters (mean difference -6% prevalence; 95% CI -17% to 6%; P = 0.33). These results suggest that reductions in malaria parasitemia may not be a major contributor to the effect of azithromycin on child mortality in settings in which SMC is administered.

Indexed as

AntimalarialsAzithromycinMalariaMalaria, FalciparumParasitemiaBurkina FasoChild MortalityChild, PreschoolFemaleHumansInfantMaleMass Drug AdministrationAntimalarialsAzithromycin

Identifiers

PMID40527304
PMCPMC12410222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.